SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

TuHURA Biosciences, Inc./NV
Date: Aug. 28, 2025 · CIK: 0001498382 · Accession: 0000000000-25-009257

Offering / Registration Process Regulatory Compliance Capital Structure

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-289532

Date
August 28, 2025
Author
Finance
Form
UPLOAD
Company
TuHURA Biosciences, Inc./NV

Letter

Re: TuHURA Biosciences, Inc. Registration Statement on Form S-1 Response dated August 25, 2025 File No. 333-289532 Dear James Bianco:

August 28, 2025

James Bianco Chief Executive Officer TuHURA Biosciences, Inc. 10500 University Center Drive, Suite 110 Tampa, FL 33612

We have reviewed your August 25, 2025 response to our comment letter and have the following comment.

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe a comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to this letter, we may have additional comments.

Registration Statement on Form S-1 General

1. We have evaluated your response and continue to note that the $3.7 million tranche is required to be purchased and funded on or before December 31, 2025. Please expand the analysis in your response to address how this would comply with the portion of Securities Act Sections Compliance and Disclosure Interpretations Question 139.11 which indicates that the closing of the private placement of the unissued securities must occur within a "short time" after the effectiveness of the resale registration statement. If the closing of this tranche will not occur within a short time after the anticipated effectiveness of this registration statement, please revise your registration statement as appropriate. August 28, 2025 Page 2

Please contact Tyler Howes at 202-551-3370 or Tim Buchmiller at 202-551-3635 with any other questions.

Sincerely,
Division of Corporation
Finance
Office of Life Sciences
cc: Curt P. Creely, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 August 28, 2025

James Bianco
Chief Executive Officer
TuHURA Biosciences, Inc.
10500 University Center Drive, Suite 110
Tampa, FL 33612

 Re: TuHURA Biosciences, Inc.
 Registration Statement on Form S-1
 Response dated August 25, 2025
 File No. 333-289532
Dear James Bianco:

 We have reviewed your August 25, 2025 response to our comment letter and
have the
following comment.

 Please respond to this letter by amending your registration statement
and providing
the requested information. If you do not believe a comment applies to your
facts and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

 After reviewing any amendment to your registration statement and the
information
you provide in response to this letter, we may have additional comments.

Registration Statement on Form S-1
General

1. We have evaluated your response and continue to note that the $3.7
million tranche is
 required to be purchased and funded on or before December 31, 2025.
Please expand
 the analysis in your response to address how this would comply with the
portion
 of Securities Act Sections Compliance and Disclosure Interpretations
Question 139.11
 which indicates that the closing of the private placement of the
unissued securities
 must occur within a "short time" after the effectiveness of the resale
registration
 statement. If the closing of this tranche will not occur within a short
time after the
 anticipated effectiveness of this registration statement, please revise
your registration
 statement as appropriate.
 August 28, 2025
Page 2

 Please contact Tyler Howes at 202-551-3370 or Tim Buchmiller at
202-551-3635
with any other questions.

 Sincerely,

 Division of Corporation
Finance
 Office of Life Sciences
cc: Curt P. Creely, Esq.
</TEXT>
</DOCUMENT>